Redhill Biopharma Current Ratio 2013-2019 | RDHL

Redhill Biopharma current ratio from 2013 to 2019. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Redhill Biopharma Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2019-09-30 $0.03B $0.01B 2.22
2019-06-30 $0.04B $0.01B 2.84
2019-03-31 $0.05B $0.01B 4.09
2018-12-31 $0.06B $0.01B 5.47
2018-09-30 $0.05B $0.01B 4.34
2018-06-30 $0.03B $0.01B 3.26
2018-03-31 $0.04B $0.01B 4.20
2017-12-31 $0.05B $0.01B 4.37
2017-09-30 $0.04B $0.01B 3.64
2017-06-30 $0.06B $0.01B 5.26
2017-03-31 $0.06B $0.01B 10.93
2016-12-31 $0.07B $0.01B 12.66
2016-09-30 $0.04B $0.01B 5.84
2016-06-30 $0.05B $0.01B 7.39
2016-03-31 $0.06B $0.01B 9.89
2015-12-31 $0.06B $0.01B 10.97
2015-09-30 $0.07B $0.00B 15.79
2015-06-30 $0.03B $0.00B 7.00
2015-03-31 $0.04B $0.01B 6.39
2014-12-31 $0.03B $0.00B 15.12
2014-09-30 $0.03B $0.00B 12.23
2014-06-30 $0.03B $0.00B 9.83
2014-03-31 $0.04B $0.00B 31.86
2013-12-31 $0.01B $0.00B 5.23
2013-09-30 $0.01B $0.00B 7.54
2013-06-30 $0.02B $0.00B 8.68
2013-03-31 $0.02B $0.00B 12.90
2012-12-31 $0.02B $0.00B 17.35
2012-09-30 $0.00B 0.00
2012-06-30 $0.00B 0.00
2012-03-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.103B $0.008B
RedHill Biopharma Ltd. is a specialty biopharmaceutical company, primarily focused on the commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases. RedHill promotes the gastrointestinal drug Aemcolo(TM) in the U.S. and is planning to launch Talicia(TM) in the U.S. for the treatment of Helicobacter pylori (H. pylori) infection in adults. RedHill's key clinical late-stage development programs include: RHB-104, with positive results from a first Phase 3 study for Crohn's disease; RHB-204, with a planned pivotal Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) infections; RHB-102 (Bekinda(TM)), for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; ABC294640 (Yeliva(TM)), a first-in-class SK2 selective inhibitor, targeting multiple oncology, inflammatory and gastrointestinal indications, with an ongoing Phase 2a study for cholangiocarcinoma; RHB-106, an encapsulated bowel preparation, and RHB-107.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $64.662B 37.40
Takeda Pharmaceutical (TAK) Japan $56.763B 10.06
Astellas Pharma (ALPMY) Japan $30.561B 15.26
Eisai (ESALY) Japan $22.232B 42.86
UCB SA (UCBJF) Belgium $18.867B 0.00
Grifols, S.A (GRFS) Spain $16.783B 21.99
Merck (MKGAF) Germany $16.058B 21.91
Ono Pharmaceutical (OPHLF) Japan $11.311B 24.18
Neurocrine Biosciences (NBIX) United States $8.671B 240.90
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $8.449B 0.00
Catalent (CTLT) United States $8.056B 33.15
Ionis Pharmaceuticals (IONS) United States $7.880B 23.64
Jazz Pharmaceuticals (JAZZ) Ireland $6.545B 7.98
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.877B 0.00
Orion OYJ (ORINY) Finland $5.871B 30.12
IPSEN SA ADR (IPSEY) France $5.799B 0.00
STADA ARZNEIMI (STDAF) Germany $5.543B 0.00
Hypermarcas (HYPMY) Brazil $4.856B 14.77
United Therapeutics (UTHR) United States $4.643B 0.00
Nektar Therapeutics (NKTR) United States $3.766B 0.00
Evotec AG (EVTCY) Germany $3.729B 60.18
Arrowhead Pharmaceuticals (ARWR) United States $3.666B 68.04
FibroGen (FGEN) United States $3.618B 106.33
PTC Therapeutics (PTCT) United States $3.349B 0.00
Sage Therapeutics (SAGE) United States $3.298B 0.00
Taro Pharmaceutical Industries (TARO) Israel $2.796B 11.31
ChemoCentryx (CCXI) United States $2.673B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $2.052B 0.00
Xencor (XNCR) United States $1.899B 77.56
Pacira Pharmaceuticals (PCRX) United States $1.897B 51.88
Ironwood Pharmaceuticals (IRWD) United States $1.751B 21.29
Heron Therapeutics (HRTX) United States $1.663B 0.00
Tilray (TLRY) Canada $1.597B 0.00
Corcept Therapeutics (CORT) United States $1.552B 17.36
Endo (ENDP) Ireland $1.440B 2.66
USANA Health Sciences (USNA) United States $1.416B 14.87
CLINIGEN GP (CLIGF) United Kingdom $1.392B 0.00
Theravance Biopharma (TBPH) Cayman Islands $1.349B 0.00
Zogenix (ZGNX) United States $1.153B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.152B 16.04
Akebia Therapeutics (AKBA) United States $1.050B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.017B 31.51
Portola Pharmaceuticals (PTLA) United States $0.974B 0.00
Karyopharm Therapeutics (KPTI) United States $0.903B 0.00
Aerie Pharmaceuticals (AERI) United States $0.870B 0.00
Radius Health (RDUS) United States $0.825B 0.00
Collegium Pharmaceutical (COLL) United States $0.757B 0.00
ImmunoGen (IMGN) United States $0.695B 0.00
Flexion Therapeutics (FLXN) United States $0.623B 0.00
Molecular Templates (MTEM) United States $0.608B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.528B 0.00
TherapeuticsMD (TXMD) United States $0.483B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.480B 58.25
Ardelyx (ARDX) United States $0.450B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.440B 18.99
Translate Bio (TBIO) United States $0.435B 0.00
Innate Pharma SA (IPHYF) France $0.423B 0.00
Organogenesis Holdings (ORGO) United States $0.406B 0.00
Calithera Biosciences (CALA) United States $0.391B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.388B 0.00
Siga Technologies (SIGA) United States $0.379B 8.67
BioCryst Pharmaceuticals (BCRX) United States $0.375B 0.00
Indivior (INVVY) United States $0.373B 2.22
DURECT (DRRX) United States $0.369B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.364B 0.00
Lannett Co Inc (LCI) United States $0.363B 5.84
Harpoon Therapeutics (HARP) United States $0.363B 0.00
Recro Pharma (REPH) United States $0.349B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.341B 0.00
Concert Pharmaceuticals (CNCE) United States $0.323B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.323B 0.00
Rafael Holdings (RFL) United States $0.308B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.295B 0.00
OptiNose (OPTN) United States $0.267B 0.00
KalVista Pharmaceuticals (KALV) United States $0.245B 0.00
Ocular Therapeutix (OCUL) United States $0.238B 0.00
MEI Pharma (MEIP) United States $0.229B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.222B 0.00
Aptorum Group (APM) Hong Kong, SAR China $0.194B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.188B 0.00
Taiwan Liposome (TLC) Taiwan $0.186B 0.00
Nature's Sunshine Products (NATR) United States $0.184B 31.67
Matinas Biopharma Holdings (MTNB) United States $0.176B 0.00
Jounce Therapeutics (JNCE) United States $0.176B 2.35
IMV INC (IMV) Canada $0.135B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.122B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.114B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.113B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.107B 0.00
CannTrust Holdings (CTST) Canada $0.106B 0.00
Xeris Pharmaceuticals (XERS) United States $0.104B 0.00
Aquestive Therapeutics (AQST) United States $0.100B 0.00
Otonomy (OTIC) United States $0.100B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.090B 0.00
VAXART, INC (VXRT) United States $0.079B 0.00
Neos Therapeutics (NEOS) United States $0.078B 0.00
Champions Oncology (CSBR) United States $0.075B 0.00
CV Sciences (CVSI) United States $0.073B 0.00
Infinity Pharmaceuticals (INFI) United States $0.072B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.067B 0.00
Onconova Therapeutics (ONTX) United States $0.067B 0.00
MediWound (MDWD) Israel $0.065B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.063B 18.91
RENEURON GP (RNUGF) United Kingdom $0.061B 0.00
CTI BioPharma (CTIC) United States $0.060B 0.00
Nivalis Therapeutics (ALPN) United States $0.059B 0.00
SCYNEXIS (SCYX) United States $0.057B 0.00
IsoRay (ISR) United States $0.056B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.053B 0.00
Aclaris Therapeutics (ACRS) United States $0.051B 0.00
Natural Alternatives (NAII) United States $0.051B 23.13
Opiant Pharmaceuticals (OPNT) United States $0.050B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.045B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.044B 0.00
AgeX Therapeutics (AGE) United States $0.044B 0.00
Forward Pharma (FWP) Denmark $0.043B 0.00
Iterum Therapeutics (ITRM) Ireland $0.041B 0.00
Mannatechorporated (MTEX) United States $0.038B 0.00
PolarityTE (PTE) United States $0.037B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.034B 0.00
Jaguar Animal Health (JAGX) United States $0.032B 0.00
ElectroCore (ECOR) United States $0.028B 0.00
Biomerica (BMRA) United States $0.027B 0.00
PharmAthene (ALT) United States $0.026B 0.00
China SXT Pharmaceuticals (SXTC) China $0.025B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.025B 0.00
Vical (BBI) United States $0.024B 0.00
ProPhase Labs (PRPH) United States $0.020B 0.00
India Globalization Capital (IGC) United States $0.019B 0.00
Cardiome Pharma (CORV) Canada $0.019B 0.00
Bio-Path Holdings (BPTH) United States $0.017B 0.00
NovaBay Pharmaceuticals (NBY) United States $0.017B 0.00
Shineco (TYHT) China $0.016B 0.00
Regulus Therapeutics (RGLS) United States $0.015B 0.00
Lipocine (LPCN) United States $0.013B 0.00
Cyanotech (CYAN) United States $0.013B 0.00
Heat Biologics (HTBX) United States $0.013B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.013B 0.00
HANCOCK JAFFE (HJLI) United States $0.013B 0.00
Novan (NOVN) United States $0.012B 0.00
Hemispherx BioPharma (AIM) United States $0.010B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.009B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.007B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.007B 0.00
Xenetic Biosciences (XBIO) United States $0.004B 0.00
Flex Pharma (SLRX) United States $0.004B 0.00
Midatech Pharma (MTP) United Kingdom $0.002B 0.00
RXi Pharmaceuticals (PHIO) United States $0.002B 0.00
Can-Fite Biopharma (CANF) Israel $0.002B 0.00